Scientists have long attempted to create vaccines that coax the immune system into recognizing the fusion (F) proteins present on the surfaces of RSV, hMPV and related viruses. These proteins play ...

Jason McLellan, professor in the Department of Molecular Biosciences and Robert A. Welch Chair in Chemistry at UT, will be ...

First, they must enter the host cells, which RSV does using its fusion (F) protein. Vaccines induce antibodies that bind to pathogens. Neutralizing antibodies bind to crucial sites, such as part ...

McLellan, who will be inducted in Washington, D.C. on May 8, is among the youngest new inductees in hall of fame history.

Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized blue) and tagged with antibodies (colorized yellow) against the virus' fusion protein — the target of ...

The two vaccines induce the immune system to target a critical protein on the surface of RSV, the F protein, in its pre-infection form, known as pre-fusion F. High levels of antibodies against pre ...

The acquisition focuses on sisunotavir, an RSV fusion inhibitor that UK-based ReViral ... including a follow-up RSV candidate targeting the viral N protein that is in phase 1 testing.

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

The adjuvanted RSV prefusion F protein-based vaccine RSVPreF3-AS01E ... tended to have higher levels of RSV-neutralizing, anti-pre-fusion F antibodies," according to a statement by Werbel.

The two vaccines induce the immune system to target a critical protein on the surface of RSV, the F protein, in its pre-infection form, known as pre-fusion F. High levels of antibodies against pre ...